Loading
NASDAQHealthcareBiotechnology
Latest quote
$12.86
+$0.12 · +0.94%
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Previous close
$12.86
+$0.12 · +0.94%
Pre-market
$12.7825
−$0.0775 · -0.60%
Sep 8, 8:27 AM ET
Regular session · ET · Market data may be delayed.
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Day range
Current $12.86
52-week range
Current $12.86
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
35
Expensive
Sentiment
58
Mixed
Risk
54
Elevated Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Day range
Current $12.86
52-week range
Current $12.86
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 1.22M USD | 1.11M USD | 1.03M USD | — | — |
| Gross profit | −1.22M USD | −1.11M USD | −1.03M USD | — | — |
| Research and development | 109.82M USD | 114.07M USD | 85.17M USD | 61.68M USD | 56.86M USD |
| Selling, general, and administrative | 33.19M USD | 28.82M USD | 25.61M USD | 25.09M USD | 22.01M USD |
| Operating expenses | 141.78M USD | 141.79M USD | 109.75M USD | 91.77M USD | 78.87M USD |
| Interest income | — | — | 10.08M USD | 2.65M USD | 141K USD |
| Interest expense | — | — | — | 2.65M USD | — |
| Depreciation and amortization | 1.22M USD | 1.11M USD | 1.03M USD | 966K USD | 897K USD |
| Operating income | −143M USD | −142.9M USD | −110.78M USD | −91.77M USD | −78.87M USD |
| Net income | −129.47M USD | −127.85M USD | −100.7M USD | −89.12M USD | −78.72M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$21.00
63.30% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI44.36M0.39%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI32.79M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM24.42M0.03%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF10.45M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN6.1M0.04%14.61B USD0.24%$224.62+0.40%
iShares Biotechnology ETFIBB5.93M0.05%10.73B USD0.44%$211.92-0.88%
Schwab U.S. Small-Cap ETFSCHA4.97M0.02%22.93B USD0.03%$34.55+1.01%
Vanguard Russell 2000 ETFVTWO4.64M0.03%17.4B USD0.06%$119.62+0.25%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
